SDZ-62-434 | CAS#115621-95-9 | CAS#115621-81-3 | Platelet Activating Factor Inhibitor

MedKoo Cat#: 528401 | Name: SDZ-62-434

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SDZ-62-434 is a platelet activating factor inhibitor potentially for the treatment of cancer. Anti-inflammatory effects of SDZ-62-434 seem to be mediated by interrupting the early-activated intracellular signaling cascades composed of phosphoinositide 3-kinase (PI3K)/Akt and NF-kappaB but not Janus kinase-2 (JAK-2), extracellular signal-regulated kinase (ERK), p38, or C-Jun N-terminal kinase (JNK), according to pharmacological, biochemical and functional analyses.

Chemical Structure

SDZ-62-434

CAS#115621-95-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 528401

Name: SDZ-62-434

CAS#: 115621-95-9 (HCl)

Chemical Formula: C22H25Cl2N3

Exact Mass:

Molecular Weight: 402.36

Elemental Analysis: C, 65.67; H, 6.26; Cl, 17.62; N, 10.44

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

115621-95-9 (HCl) 115621-81-3 (free)

Synonym

SDZ-62-434; SDZ 62 434; SDZ62434

IUPAC/Chemical Name

5-(4-(piperidin-1-yl)phenyl)-2,3-dihydroimidazo[2,1-a]isoquinoline dihydrochloride

InChi Key

BKOQATFPPHQOQH-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H23N3.2ClH/c1-4-13-24(14-5-1)19-10-8-17(9-11-19)21-16-18-6-2-3-7-20(18)22-23-12-15-25(21)22;;/h2-3,6-11,16H,1,4-5,12-15H2;2*1H

SMILES Code

[H]Cl.[H]Cl.C12=NCCN1C(C3=CC=C(N4CCCCC4)C=C3)=CC5=C2C=CC=C5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 402.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lee JY, Rhee MH, Cho JY. Novel modulatory effects of SDZ 62-434 on inflammatory events in activated macrophage-like and monocytic cells. Naunyn Schmiedebergs Arch Pharmacol. 2008 Apr;377(2):111-24. doi: 10.1007/s00210-008-0266-y. PubMed PMID: 18299817. 2: Cheon SH, Park JS, Jeong SH, Chung BH, Choi BG, Cho WJ, Kang BH, Lee CO. Synthesis and structure-activity relationship studies of 2,3-dihydroimidazo[2,1-a]isoquinoline analogs as antitumor agents. Arch Pharm Res. 1997 Apr;20(2):138-43. PubMed PMID: 18975191. 3: Houlihan WJ, Munder PG, Handley DA, Nemecek GA. Preclinical pharmacology and possible mechanism of action of the novel antitumor agent 5-(4'-piperidinomethylphenyl)-2,3-dihydroimidazo [2,1-a]isoquinoline. Arzneimittelforschung. 1995 Oct;45(10):1133-7. PubMed PMID: 8595076. 4: Houlihan WJ, Munder PG, Handley DA, Cheon SH, Parrino VA. Antitumor activity of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinolines. J Med Chem. 1995 Jan 20;38(2):234-40. PubMed PMID: 7830265. 5: Brunton VG, Workman P. In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. Br J Cancer. 1993 May;67(5):989-95. PubMed PMID: 8388233; PubMed Central PMCID: PMC1968438. 6: Koenigsmann M, Zafferani M, Danhauser-Riedl S, Reufi B, Houlihan WJ, Thiel E, Berdel WE. Lack of therapeutic effects of platelet activating factor antagonists in WEHI-3B leukemia, human xenotransplanted colorectal and lung cancer and Lewis-lung tumor in vivo. Cancer Lett. 1992 Dec 24;67(2-3):145-56. PubMed PMID: 1483263. 7: Valone FH, Ruis NM. Stimulation of tumour necrosis factor release by cytotoxic analogues of platelet-activating factor. Immunology. 1992 May;76(1):24-9. PubMed PMID: 1628897; PubMed Central PMCID: PMC1421731. 8: Danhauser-Riedl S, Felix SB, Houlihan WJ, Zafferani M, Steinhauser G, Oberberg D, Kalvelage H, Busch R, Rastetter J, Berdel WE. Some antagonists of platelet activating factor are cytotoxic for human malignant cell lines. Cancer Res. 1991 Jan 1;51(1):43-8. PubMed PMID: 1988103.